Endometrial Carcinoma (EC)
Endometrial Carcinoma arises from the uterine lining and includes several molecular classes shaped by mismatch repair status and other genomic alterations.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Endometrial Carcinoma (EC) in FDA labeling.
| Biomarker | Biomarker criteria | Therapies |
|---|---|---|
| Not MSI-High |
| |
| proficient mismatch repair (pMMR) proteins |
|
Defined at the solid tumor level and applicable to Endometrial Carcinoma (EC) and other solid tumor cancers.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Endometrial Carcinoma (EC). Select a therapy to view the specific approval and eligible tests.
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6)
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High)
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High); TMB (TMB ≥ 10 mutations per megabase)
Not MSI-High (Not Microsatellite Instability-High (Not MSI-H)); proficient mismatch repair (pMMR) proteins (MLH1, PMS2, MSH2 and MSH6)
RET (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)